Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer
NCT ID: NCT02582801
Last Updated: 2019-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
46 participants
INTERVENTIONAL
2015-10-31
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of 18F-FAPI-RGD in Breast Tumors
NCT05976620
Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics
NCT03094897
Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy
NCT05828238
Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy
NCT06909604
Characterizing Breast Cancer With Al18F-NOTA-FAPI-04 PET/CT (PFB-02)
NCT05574920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer
Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
18F-Alfatide Ⅱ PET/CT
Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
benign breast lesions
Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
18F-Alfatide Ⅱ PET/CT
Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-Alfatide Ⅱ PET/CT
Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiang Wu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiang Wu
Medical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guangming Lu, Professor
Role: STUDY_CHAIR
Jinling Hospital, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jinling Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2. Epub 2015 Jul 1.
Wang SY, Bao X, Wang MW, Zhang YP, Zhang YJ, Zhang JP. Radiation dosimetry estimates of (18)F-alfatide II based on whole-body PET imaging of mice. Appl Radiat Isot. 2015 Nov;105:1-5. doi: 10.1016/j.apradiso.2015.07.013. Epub 2015 Jul 13.
Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015 Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. eCollection 2015.
Wu C, Yue X, Lang L, Kiesewetter DO, Li F, Zhu Z, Niu G, Chen X. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics. 2014 Feb 26;4(5):546-55. doi: 10.7150/thno.8159. eCollection 2014.
Guo J, Guo N, Lang L, Kiesewetter DO, Xie Q, Li Q, Eden HS, Niu G, Chen X. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014 Jan;55(1):154-60. doi: 10.2967/jnumed.113.122069. Epub 2013 Nov 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Molecular Imaging
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.